Guenther Hochhaus, Ph.D.
Professor
About Guenther Hochhaus
Hochhaus evaluates anti-asthma drugs in the body (pharmacokinetics) to understand the relationship between the drug properties and the pharmacodynamic effects. His work linking pharmacokinetic-pharmacodynamic approaches with a rational drug delivery design has proven to be a powerful tool in streamlining drug development for inhalation drugs. Current research focuses on the use of Pharmacometrics in regulatory science of inhalation drugs. To provide a strong research program in pharmaceutics and actively seek outside support; to participate in teaching and education of undergraduate, graduate students and postdoctoral associates. The courses include undergraduate class PHA 5132, and graduate class “Pharmaceutical Analysis I (PHA 6416)”.
Teaching Profile
Courses Taught
2016,2018-2020,2020
PHA5878C Pt Care 3: Cv and Pulm
2008-2023
PHA7980 Research for Doctoral Dissertation
2008-2021
PHA7979 Advanced Research
2007,2009-2011,2011-2015,2013-2019,2015-2020,2017-2020,2019-2020
PHA6416 Pharmaceutical Analysis I
2010-2014,2020-2021
PHA6971 Research for Master’s Thesis
2017-2018,2020
PHA6910 Supervised Research
2016-2019,2021-2023
PHA5132 Prin Drug Ther Indiv
2006,2014-2017,2017
PHA6938 Research Seminar
2006-2015
PHA5127 Dose Optimization 1
2015
PHA4912 Undergraduate Research in Pharmaceutics
2013-2014
PHA5905 Clin Pharm Research
2010-2011
PHA6936 Adv Topics Pharm Sci
2011
PHA6935 Sel Topics Pharmacy
Research Profile
Open Researcher and Contributor ID (ORCID)
0000-0002-7406-5558
Publications
2022
Effects of Formulation and Actuator Design on Spray Velocity of Mometasone Furoate Metered Dose Inhalers
Respiratory Drug Delivery 2022.
2022(1):411-416
2022
Evaluating Particle Size Differences of Suspension-based Nasal Sprays Through In Vitro and Pharmacokinetic Approaches
Respiratory Drug Delivery 2022.
1:47-54
2022
iBCS: 1. Principles and Framework of an Inhalation-Based Biopharmaceutics Classification System.
Molecular pharmaceutics.
19(7):2032-2039
[DOI] 10.1021/acs.molpharmaceut.2c00113.
[PMID] 35576168.
2022
iBCS: 2. Mechanistic Modeling of Pulmonary Availability of Inhaled Drugs versus Critical Product Attributes.
Molecular pharmaceutics.
19(7):2040-2047
[DOI] 10.1021/acs.molpharmaceut.2c00112.
[PMID] 35609877.
2022
Mechanistic modeling of generic orally inhaled drug products: A workshop summary report
CPT: Pharmacometrics & Systems Pharmacology.
[DOI] 10.1002/psp4.12889.
2022
The Effects of Inhalation Flow Rate on Aerodynamic Particle Size Distribution (APSD) of Commercial Solution and Suspension Metered Dose Inhalers (MDIs).
Respiratory drug delivery 2022.
1:417-422
2021
Can Pharmacokinetic Studies Assess the Pulmonary Fate of Dry Powder Inhaler Formulations of Fluticasone Propionate?
The AAPS Journal.
23(3)
[DOI] 10.1208/s12248-021-00569-x.
2021
Dissolution and drug release
Inhaled Medicines.
225-266
[DOI] 10.1016/b978-0-12-814974-4.00008-0.
2021
Factors Influencing Plume Characteristics of Metered Dose Inhalers (MDIs) Following Passage Through Bio-relevant Mouth-Throat Models.
Respiratory Drug Delivery 2021.
1:301-306
2021
Optimization of the Transwell® System for Assessing the Dissolution Behavior of Orally Inhaled Drug Products through In Vitro and In Silico Approaches.
Pharmaceutics.
13(8)
[DOI] 10.3390/pharmaceutics13081109.
[PMID] 34452069.
2021
Semi-mechanistic PK/PD model to assess pulmonary targeting of beclomethasone dipropionate and its active metabolite
European Journal of Pharmaceutical Sciences.
159
[DOI] 10.1016/j.ejps.2021.105699.
2021
Systematic Evaluation of the Effect of Formulation Variables on In Vitro Performance of Mometasone Furoate Suspension-Metered Dose Inhalers.
The AAPS journal.
24(1)
[DOI] 10.1208/s12248-021-00638-1.
[PMID] 34874508.
2020
Coating Stages of Next Generation Impactor (NGI) When Testing Metered Dose Inhalers (MDIs) – A Comparative Study on US Commercial MDI Products.
Respiratory Drug Delivery 2020.
2:463-468
2020
Effects of Formulation and Actuator Design on Spray Pattern and Plume Geometry of Mometasone Furoate Metered Dose Inhalers.
Respiratory Drug Delivery 2020.
503-507
2020
Huntington’s Disease Progression: A Population Modeling Approach to Characterization Using Clinical Rating Scales.
Journal of clinical pharmacology.
60(8):1051-1060
[DOI] 10.1002/jcph.1598.
[PMID] 32416008.
2020
Quantitative Assessment of Pulmonary Targeting of Inhaled Corticosteroids Using Ex Vivo Receptor Binding Studies.
The AAPS journal.
22(2)
[DOI] 10.1208/s12248-019-0404-0.
[PMID] 32002694.
2020
The Effects of Formulation Factors and Actuator Design on Mometasone Furoate Metered Dose Inhaler In Vitro Aerosolization Performance
Respiratory Drug Delivery 2020.
3:497-501
2020
Unraveling the Pulmonary Fate of Fluticasone and Friends: Meeting the Physiologic and Pharmacokinetic Challenges
Respiratory Drug Delivery 2020..
1:139-146
2020
Urgent Appeal from International Society for Aerosols in Medicine (ISAM) During COVID-19: Clinical Decision Makers and Governmental Agencies Should Consider the Inhaled Route of Administration: A Statement from the ISAM Regulatory and Standardization Issues Networking Group.
Journal of aerosol medicine and pulmonary drug delivery.
33(4):235-238
[DOI] 10.1089/jamp.2020.1622.
[PMID] 32589076.
2020
Workshop Report: USP Workshop on Advancements in In Vitro Performance Testing of Drug Products
Dissolution Technologies.
27(2):52-70
[DOI] 10.14227/dt270220p52.
2019
Characterization of a dextran-budesonide prodrug for inhalation therapy
European Journal of Pharmaceutical Sciences.
129:58-67
[DOI] 10.1016/j.ejps.2018.11.038.
2019
Pharmacokinetic and pharmacodynamic modeling of gut hormone peptide YY(3-36) after pulmonary delivery.
Drug development and industrial pharmacy.
45(7):1101-1110
[DOI] 10.1080/03639045.2019.1593443.
[PMID] 31039626.
2018
Effects of lipid formulations on clove extract spray dried powders: comparison of physicochemical properties, storage stability and in vitro intestinal permeation
Pharmaceutical Development and Technology.
23(10):1047-1056
[DOI] 10.1080/10837450.2017.1314491.
2017
Predicting Pulmonary Pharmacokinetics from In Vitro Properties of Dry Powder Inhalers
Pharmaceutical Research.
34(12):2541-2556
[DOI] 10.1007/s11095-017-2235-y.
2015
A Systematic Analysis of the Sensitivity of Plasma Pharmacokinetics to Detect Differences in the Pulmonary Performance of Inhaled Fluticasone Propionate Products Using a Model-Based Simulation Approach.
The AAPS journal.
17(4):999-1010
[DOI] 10.1208/s12248-015-9768-y.
[PMID] 25933600.
2015
Application of the modified chi-square ratio statistic in a stepwise procedure for cascade impactor equivalence testing.
The AAPS journal.
17(2):370-9
[DOI] 10.1208/s12248-014-9698-0.
[PMID] 25515206.
2015
Cholestenoic Acid, An Endogenous Cholesterol Metabolite, Is a Potent Gamma-Secretase Modulator
Molecular neurodegeneration.
10
[DOI] 10.1186/s13024-015-0021-z.
[PMID] 26169917.
2015
Current Scientific and Regulatory Approaches for Development of Orally Inhaled and Nasal Drug Products: Overview of the IPAC-RS/University of Florida Orlando Inhalation Conference.
The AAPS journal.
17(5):1305-11
[DOI] 10.1208/s12248-015-9791-z.
[PMID] 26033698.
2015
Pharmacokinetics of Orally Inhaled Drug Products
Aaps Journal.
17(3):769-775
[DOI] 10.1208/s12248-015-9736-6.
[PMID] 25762449.
2015
Quantitative characterization of circadian rhythm of pulmonary function in asthmatic patients treated with inhaled corticosteroids.
Journal of pharmacokinetics and pharmacodynamics.
42(4):391-9
[DOI] 10.1007/s10928-015-9420-6.
[PMID] 26099861.
2014
Pharmacokinetics and pharmacodynamics of glycopyrrolate following a continuous-rate infusion in the horse.
Journal of veterinary pharmacology and therapeutics.
37(2):133-44
[DOI] 10.1111/jvp.12074.
[PMID] 23902283.
2014
Population pharmacokinetic modeling of the unbound levofloxacin concentrations in rat plasma and prostate tissue measured by microdialysis.
Antimicrobial agents and chemotherapy.
58(2):678-86
[DOI] 10.1128/AAC.01884-13.
[PMID] 24217697.
2013
A pharmacokinetic simulation tool for inhaled corticosteroids.
The AAPS journal.
15(1):159-71
[DOI] 10.1208/s12248-012-9420-z.
[PMID] 23139018.
2013
A sensitivity analysis of the modified chi-square ratio statistic for equivalence testing of aerodynamic particle size distribution.
The AAPS journal.
15(2):465-76
[DOI] 10.1208/s12248-013-9453-y.
[PMID] 23344791.
2013
A stability analysis of a modified version of the chi-square ratio statistic: implications for equivalence testing of aerodynamic particle size distribution.
The AAPS journal.
15(1):1-9
[DOI] 10.1208/s12248-012-9410-1.
[PMID] 23008161.
2013
Bioequivalence of inhaled drugs: fundamentals, challenges and perspectives.
Therapeutic delivery.
4(3):343-67
[DOI] 10.4155/tde.12.161.
[PMID] 23442081.
2013
Development and Validation of Liquid Chromatography-Tandem Mass Spectrometry Method for Detection and Quantification of Flunisolide in Tissue Culture Medium
Analytical Letters.
46(9):1355-1363
[DOI] 10.1080/00032719.2013.766797.
2013
Development of a placebo effect model combined with a dropout model for bipolar disorder.
Journal of pharmacokinetics and pharmacodynamics.
40(3):359-68
[DOI] 10.1007/s10928-013-9305-5.
[PMID] 23456101.
2013
Development of An in Vitro Test Method for Dissolution of Inhaled Corticosteroids
Journal of Aerosol Medicine and Pulmonary Drug Delivery.
26:A58-A59
2013
Evaluation of the Feasibility of Pharmacodynamic Bioequivalence Studies of Inhaled Corticosteroids Through Monte Carlo Simulations
Journal of Aerosol Medicine and Pulmonary Drug Delivery.
26
2013
Preliminary Development of Disease Progression Model for Huntington’s Disease
Clinical Pharmacology & Therapeutics.
93
2012
Nonlinear pharmacokinetics of visnagin in rats after intravenous bolus administration.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
45(1-2):79-89
[DOI] 10.1016/j.ejps.2011.10.023.
[PMID] 22085634.
2012
Pharmacokinetic evaluation of visnagin and Ammi visnaga aqueous extract after oral administration in rats.
Planta medica.
78(17):1831-6
[DOI] 10.1055/s-0032-1315393.
[PMID] 23096256.
2011
Systemic exposure to fluticasone MDI delivered through antistatic chambers.
The Journal of allergy and clinical immunology.
128(5):1113-5.e1
[DOI] 10.1016/j.jaci.2011.06.014.
[PMID] 21783234.
2010
Feasibility of localized immunosuppression: 1. Exploratory studies with glucocorticoids in a biohybrid device designed for cell transplantation.
Die Pharmazie.
65(6):421-8
[PMID] 20614690.
2010
Feasibility of localized immunosuppression: 2. PLA microspheres for the sustained local delivery of a soft immunosuppressant.
Die Pharmazie.
65(6):429-35
[PMID] 20614691.
2010
Simulation-Based Evaluation of T(Max) as a Pharmacokinteic Parameter To Assess Bioequivalence of Inhaled Corticosteroids
.
50
2010
Targeting retinal and choroid neovascularization using the small molecule inhibitor carboxyamidotriazole.
Brain research bulletin.
81(2-3):320-6
[DOI] 10.1016/j.brainresbull.2009.08.001.
[PMID] 19679174.
2009
Budesonide and ciclesonide: effect of tissue binding on pulmonary receptor binding.
Drug metabolism and disposition: the biological fate of chemicals.
37(7):1421-6
[DOI] 10.1124/dmd.108.026039.
[PMID] 19364829.
2009
Chronic blockade of hindbrain glucocorticoid receptors reduces blood pressure responses to novel stress and attenuates adaptation to repeated stress.
American journal of physiology. Regulatory, integrative and comparative physiology.
296(5):R1445-54
[DOI] 10.1152/ajpregu.00095.2008.
[PMID] 19279295.
2008
Evaluation of the Administration Time Effect On the Cumulative Cortisol Suppression and Cumulative Lymphocytes Suppression for Once-Daily Inhaled Corticosteroids: a Population Modeling/Simulation Approach
Journal of clinical pharmacology.
48(9):1069-1080
[DOI] 10.1177/0091270008320607.
[PMID] 18728243.
2008
Fluticasone Furoate Nasal Spray in Allergic Rhinitis
Drugs of today (Barcelona, Spain : 1998).
44(4):251-260
[DOI] 10.1358/dot.2008.44.4.1173289.
[PMID] 18536783.
2008
Nonpeptide somatostatin receptor agonists specifically target ocular neovascularization via the somatostatin type 2 receptor.
Investigative ophthalmology & visual science.
49(11):5094-102
[DOI] 10.1167/iovs.08-2289.
[PMID] 18599562.
2008
Pharmacokinetic/pharmacodynamic profile of mometasone furoate nasal spray: potential effects on clinical safety and efficacy.
Clinical therapeutics.
30(1):1-13
[DOI] 10.1016/j.clinthera.2008.01.005.
[PMID] 18343239.
2008
Relative Receptor Affinity Comparisons Among Inhaled/Intranasal Corticosteroids: Perspectives On Clinical Relevance
Respiratory Research.
9
[DOI] 10.1186/1465-9921-9-75.
[PMID] 19025651.
2008
Simultaneous Determination of Dexamethasone, Dexamethasone 21-Acetate, and Paclitaxel in a Simulated Biological Matrix By Rp-Hplc: Assay Development and Validation
Journal of Liquid Chromatography and Related Technologies.
31(10):1478-1491
[DOI] 10.1080/10826070802039515.
2008
Slow Release Formulations of Inhaled Rifampin
Aaps Journal.
10(2):342-348
[DOI] 10.1208/s12248-008-9044-5.
[PMID] 18584334.
2008
Transrepression and transactivation potencies of inhaled glucocorticoids.
Die Pharmazie.
63(12):893-8
[PMID] 19177906.
2006
Differences in the glucocorticoid to progesterone receptor selectivity of inhaled glucocorticoids.
The European respiratory journal.
27(3):511-6
[PMID] 16507850.
2006
Do intensive care patients need an individualized dosing regimen for levofloxacin?
International journal of clinical pharmacology and therapeutics.
44(6):262-9
[PMID] 16800098.
2006
Influence of the N-acetylation polymorphism on the metabolism of talampanel: an investigation in fasted and fed subjects genotyped for NAT2 variants.
Die Pharmazie.
61(2):125-34
[PMID] 16526560.
2006
Lung bioavailability of hydrofluoroalkane fluticasone in young children when delivered by an antistatic chamber/mask.
The Journal of pediatrics.
149(6):793-7
[PMID] 17137894.
2006
Metabolism of mometasone furoate and biological activity of the metabolites.
Drug metabolism and disposition: the biological fate of chemicals.
34(2):225-33
[PMID] 16251254.
2006
Pharmacokinetic/pharmacodynamic modeling of total lymphocytes and selected subtypes after oral budesonide.
Journal of pharmacokinetics and pharmacodynamics.
33(4):441-59
[PMID] 16633890.
2006
Pharmacological effects of some newly developed soft anticholinergics and a receptor-binding QSAR study.
Die Pharmazie.
61(2):148-53
[PMID] 16526564.
2006
Pulmonary targeting of sustained release formulation of budesonide in neonatal rats.
Journal of drug targeting.
14(10):680-6
[PMID] 17162737.
2005
A sensitive liquid chromatography-tandem mass spectrometry method for the quantification of mometasone furoate in human plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
819(1):175-9
[PMID] 15797536.
2005
Brain permeability of inhaled corticosteroids.
The Journal of pharmacy and pharmacology.
57(9):1159-67
[PMID] 16105236.
2005
Interpretation of absorption rate data for inhaled fluticasone propionate obtained in compartmental pharmacokinetic modeling.
International journal of clinical pharmacology and therapeutics.
43(3):117-22
[PMID] 15792395.
2005
What is the best marker for inhaled corticosteroid safety?
Allergy and asthma proceedings.
26(2):89-93
[PMID] 15971465.
2004
A novel method for polymer coating of plasmid DNA: initial investigations into the use of pulse laser deposition and gene delivery.
Journal of drug targeting.
12(4):237-41
[PMID] 15506172.
2004
Age effects on the pharmacokinetics of tityustoxin from Tityus serrulatus scorpion venom in rats.
Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.
37(3):385-90
[PMID] 15060708.
2004
Characterization of degradation products of mometasone furoate.
Die Pharmazie.
59(5):367-73
[PMID] 15212303.
2004
Drugs used in the treatment of opioid tolerance and physical dependence: a review.
International journal of clinical pharmacology and therapeutics.
42(4):191-203
[PMID] 15124977.
2004
Evaluation of oral budesonide in the treatment of active distal ulcerative colitis.
Drugs of today (Barcelona, Spain : 1998).
40(7):589-601
[PMID] 15510233.
2004
How the lung handles drugs: pharmacokinetics and pharmacodynamics of inhaled corticosteroids.
Proceedings of the American Thoracic Society.
1(4):356-63
[PMID] 16113458.
2004
In vitro performance characteristics of valved holding chamber and spacer devices with a fluticasone metered-dose inhaler.
Pharmacotherapy.
24(2):159-66
[DOI] 10.1592/phco.24.2.159.33147.
[PMID] 14998215.
2004
Metabolism of dynorphin A(1-13).
Die Pharmazie.
59(5):339-43
[PMID] 15212298.
2004
New developments in corticosteroids.
Proceedings of the American Thoracic Society.
1(3):269-74
[DOI] 10.1513/pats.200402-007MS.
[PMID] 16113445.
2004
Possibilities in improvement of glucocorticoid treatments in asthma with special reference to loteprednol etabonate.
Die Pharmazie.
59(5):409-11
[PMID] 15212311.
2004
Stabilized dynorphin derivatives for modulating antinociceptive activity in morphine tolerant rats: effect of different routes of administration.
The AAPS journal.
6(4)
[PMID] 15760101.
2003
In vitro performance of two common valved holding chambers with a chlorofluorocarbon-free beclomethasone metered-dose inhaler.
Pharmacotherapy.
23(12):1538-44
[DOI] 10.1592/phco.23.15.1538.31960.
[PMID] 14695033.
2003
Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma.
Current medical research and opinion.
19(6):491-8
[PMID] 14594521.
2003
Population pharmacokinetics and pharmacodynamics of ciclesonide.
Journal of clinical pharmacology.
43(4):365-78
[PMID] 12723457.
2003
SPE/RIA vs LC/MS for measurement of low levels of budesonide in plasma.
Biomedical chromatography : BMC.
17(1):14-20
[PMID] 12583000.
2002
In vitro deposition of fluticasone aerosol from a metered-dose inhaler with and without two common valved holding chambers.
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
88(2):204-8
[PMID] 11868926.
2001
Current concepts in pharmacokinetics and their implications for clinical medicine.
Wiener klinische Wochenschrift.
113(15-16):566-72
[PMID] 11571833.
2001
Evaluation of pulmonary absorption using pharmacokinetic methods.
Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.
14 Suppl 1:S9-17
[PMID] 11424896.
2001
Pharmacokinetics and pharmacodynamics of dexamethasone sodium-m-sulfobenzoate (DS) after intravenous and intramuscular administration: a comparison with dexamethasone phosphate (DP).
Journal of clinical pharmacology.
41(4):425-34
[PMID] 11304899.
2001
Pharmacokinetics and rectal bioavailability of hydrocortisone acetate after single and multiple administration in healthy subjects and patients.
Journal of clinical pharmacology.
41(5):536-41
[PMID] 11361050.
2001
Pharmacokinetics of plasmid DNA in the rat.
Pharmaceutical research.
18(1):67-74
[PMID] 11336355.
2001
Receptor binding studies of soft anticholinergic agents.
AAPS pharmSci.
3(4)
[PMID] 12049493.
2001
Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically clinically equivalent doses of inhaled fluticasone propionate and budesonide, given as Diskus or Turbohaler dry-powder inhalers to healthy subjects.
Journal of clinical pharmacology.
41(12):1329-38
[PMID] 11762560.
2000
A sensitive LC-MS/MS method for the quantification of fluticasone propionate in human plasma.
Journal of pharmaceutical and biomedical analysis.
22(1):123-9
[PMID] 10727131.
2000
An interactive algorithm for the assessment of cumulative cortisol suppression during inhaled corticosteroid therapy.
AAPS pharmSci.
2(3)
[PMID] 11741238.
2000
Evolution of pharmacokinetics and pharmacokinetic/dynamic correlations during the 20th century.
Journal of clinical pharmacology.
40(9):908-17
[PMID] 10975063.
2000
Loteprednol etabonate: a soft steroid for the treatment of allergic diseases of the airways.
Drugs of today (Barcelona, Spain : 1998).
36(5):313-20
[PMID] 12861354.
2000
Optimized therapeutic ratio of inhaled corticosteroids using retrometabolism.
Die Pharmazie.
55(3):223-7
[PMID] 10756545.
1999
A pharmacokinetic/pharmacodynamic approach to predict the cumulative cortisol suppression of inhaled corticosteroids.
Journal of pharmacokinetics and biopharmaceutics.
27(2):127-47
[PMID] 10567952.
1999
Analysis of leucine enkephalin by high-performance liquid chromatography using enzymatic derivatization by tyrosinase and electrochemical or fluorescence detection.
Journal of pharmaceutical and biomedical analysis.
19(6):855-64
[PMID] 10698551.
1999
Assessment of complex peptide degradation pathways via structured multicompartmental modeling approaches: the metabolism of dynorphin A1-13 and related fragments in human plasma.
Journal of pharmaceutical sciences.
88(9):938-44
[PMID] 10479358.
1999
Kinetic modeling of plasmid DNA degradation in rat plasma.
AAPS pharmSci.
1(3)
[PMID] 11741205.
1999
Mechanism-based PK/PD model for the lymphocytopenia induced by endogenous and exogenous corticosteroids.
International journal of clinical pharmacology and therapeutics.
37(8):367-76
[PMID] 10475139.
1998
A selective HPLC/RIA for the determination of budesonide.
Journal of pharmaceutical and biomedical analysis.
17(8):1235-42
[PMID] 9800642.
1998
Displacement of [3H]-L-glutamate in rat brain membranes by metabolic dynorphin fragments.
Die Pharmazie.
53(2):142-3
[PMID] 9540113.
1998
Effect of dose and release rate on pulmonary targeting of liposomal triamcinolone acetonide phosphate.
Pharmaceutical research.
15(3):461-5
[PMID] 9563078.
1998
Pharmacokinetic and pharmacodynamic aspects of salmeterol therapy.
International journal of clinical pharmacology and therapeutics.
36(12):652-60
[PMID] 9877002.
1998
Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration.
European journal of clinical pharmacology.
53(6):459-67
[PMID] 9551705.
1998
Pharmacokinetics and pharmacodynamics of inhaled corticosteroids.
The Journal of allergy and clinical immunology.
101(4 Pt 2):S440-6
[PMID] 9563369.
1998
Pharmacokinetics of intravenous dynorphin A(1-13) in opioid-naive and opioid-treated human volunteers.
Clinical pharmacology and therapeutics.
64(1):27-38
[PMID] 9695716.
1997
An HPLC/RIA method for dynorphin A1-13 and its main metabolites in human blood.
Journal of pharmaceutical and biomedical analysis.
16(1):101-9
[PMID] 9447557.
1997
Clinical PK/PD modelling as a tool in drug development of corticosteroids.
International journal of clinical pharmacology and therapeutics.
35(10):481-8
[PMID] 9352400.
1997
Dependency of cortisol suppression on the administration time of inhaled corticosteroids.
Journal of clinical pharmacology.
37(8):704-10
[PMID] 9378842.
1997
Pharmacokinetic/pharmacodynamic aspects of aerosol therapy using glucocorticoids as a model.
Journal of clinical pharmacology.
37(10):881-92
[PMID] 9505979.
1997
Pharmacokinetic/pharmacodynamic evaluation of systemic effects of flunisolide after inhalation.
Journal of clinical pharmacology.
37(10):893-903
[PMID] 9505980.
1997
Pharmacokinetics of methylprednisolone and prednisolone after single and multiple oral administration.
Journal of clinical pharmacology.
37(10):916-25
[PMID] 9505983.
1996
Interspecies comparison of in vitro plasma degradation of dynorphin A 1-13.
Die Pharmazie.
51(8):581-5
[PMID] 8794468.
1996
Metabolism of dynorphin A1-13 in human CSF.
Neurochemical research.
21(10):1213-9
[PMID] 8923483.
1996
Pharmacokinetics and pharmacodynamics of cloprednol.
International journal of clinical pharmacology and therapeutics.
34(1):1-5
[PMID] 8688990.
1996
Pulmonary targeting of liposomal triamcinolone acetonide phosphate.
Pharmaceutical research.
13(11):1699-703
[PMID] 8956337.
1995
Assessment of glucocorticoid lung targeting by ex-vivo receptor binding studies in rats.
Pharmaceutical research.
12(1):134-7
[PMID] 7724475.
1995
Metabolism of dynorphin A 1-13 in human blood and plasma.
Pharmaceutical research.
12(8):1165-70
[PMID] 7494829.
1995
Pharmacokinetic and pharmacodynamic evaluation of triamcinolone acetonide after intravenous, oral, and inhaled administration.
Journal of clinical pharmacology.
35(12):1187-93
[PMID] 8750370.
1995
Pharmacokinetic interaction between endogenous cortisol and exogenous corticosteroids.
Die Pharmazie.
50(9):610-3
[PMID] 7480097.
1995
Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone.
Pharmaceutical research.
12(7):1096-100
[PMID] 7494809.
1995
Pharmacokinetics of triamcinolone acetonide after intravenous, oral, and inhaled administration.
Journal of clinical pharmacology.
35(3):302-5
[PMID] 7608322.
1994
[Problems of equivalency points during therapy with glucocorticoids. A comparison of the clinical pharmacokinetics and pharmacodynamics of prednisolone and methylprednisolone].
Deutsche medizinische Wochenschrift (1946).
119(48):1671-6
[PMID] 7988369.
1994
Clinical pharmacology of pancreatic enzymes in patients with cystic fibrosis and in vitro performance of microencapsulated formulations.
Journal of clinical pharmacology.
34(2):158-66
[PMID] 8163716.
1994
Leucine enkephalin-tyrosinase reaction products–identification and biological activity.
Biochimica et biophysica acta.
1222(1):95-100
[PMID] 8186271.
1993
Generic and alternative brand-name pharmaceutical equivalents: select with caution.
American journal of hospital pharmacy.
50(2):323-9
[PMID] 8480793.
1993
Prednicarbate after different forms of administration. Plasma levels of drug and metabolites and effects on endogenous cortisol levels in humans.
Current problems in dermatology.
21:147-56
[PMID] 8299368.
1993
Receptor-based pharmacokinetic-pharmacodynamic analysis of corticosteroids.
Journal of clinical pharmacology.
33(2):115-23
[PMID] 8440759.
1993
Studies on the pharmacokinetics and metabolism of prednicarbate after cutaneous and oral administration.
Skin pharmacology : the official journal of the Skin Pharmacology Society.
6(3):179-86
[PMID] 8274287.
1992
A selective HPLC/RIA for dexamethasone and its prodrug dexamethasone-21-sulphobenzoate sodium in biological fluids.
Biomedical chromatography : BMC.
6(6):283-6
[PMID] 1286285.
1992
Pharmacokinetic characterization and tissue distribution of the new glucocorticoid soft drug loteprednol etabonate in rats and dogs.
Journal of pharmaceutical sciences.
81(12):1210-5
[PMID] 1491342.
1992
Pharmacokinetic/dynamic correlation of pulmonary and cardiac effects of fenoterol in asthmatic patients after different routes of administration.
Pharmaceutical research.
9(3):291-7
[PMID] 1614958.
1992
Pharmacokinetic/pharmacodynamic characteristics of the beta-2-agonists terbutaline, salbutamol and fenoterol.
International journal of clinical pharmacology, therapy, and toxicology.
30(9):342-62
[PMID] 1358833.
1992
Pharmacokinetics and pharmacodynamics of prednisolone after intravenous and oral administration.
International journal of clinical pharmacology, therapy, and toxicology.
30(9):317-24
[PMID] 1428295.
1991
A new fluorogenic assay for tyrosine-containing peptides.
Journal of pharmaceutical and biomedical analysis.
9(7):557-63
[PMID] 1817676.
1991
A selective LC/RIA for dexamethasone and its prodrug dexamethasone-21-isonicotinate in biological fluids.
Journal of pharmaceutical and biomedical analysis.
9(9):761-7
[PMID] 1821154.
1991
cAMP accumulation in opioid-sensitive SH-SY5Y neuroblastoma cells is modified by estradiol and progesterone.
Molecular and cellular endocrinology.
78(3):155-62
[PMID] 1663875.
1991
Glucocorticoid activity and structure activity relationships in a series of some novel 17 alpha-ether-substituted steroids: influence of 17 alpha-substituents.
Drug design and discovery.
8(2):117-25
[PMID] 1793774.
1991
Soft drugs–10. Blanching activity and receptor binding affinity of a new type of glucocorticoid: loteprednol etabonate.
The Journal of steroid biochemistry and molecular biology.
38(2):149-54
[PMID] 2004037.
1990
An avidin-biotin based enzyme-linked immunosorbent assay for dynorphin A 1-13.
Journal of pharmaceutical and biomedical analysis.
8(6):541-5
[PMID] 1982703.
1990
Binding affinities of rimexolone (ORG 6216), flunisolide and their putative metabolites for the glucocorticoid receptor of human synovial tissue.
Agents and actions.
30(3-4):377-80
[PMID] 2386110.
1990
Oral bioavailability of triamcinolone tablets and a triamcinolone diacetate suspension.
Pharmaceutical research.
7(5):558-60
[PMID] 1973290.
1988
[Biocytin13]dynorphin A 1-13 amide: a potential probe for the kappa-opioid receptor.
Pharmaceutical research.
5(12):790-4
[PMID] 2907785.
1988
A biotin-avidin-based enzyme immunoassay for beta h-endorphin.
Pharmaceutical research.
5(4):232-5
[PMID] 2977649.
1988
Biotinylated human beta-endorphins as probes for the opioid receptor.
The Journal of biological chemistry.
263(1):92-7
[PMID] 2826453.
1988
Differentiation of human neuroblastoma cells: marked potentiation of prostaglandin E-stimulated accumulation of cyclic AMP by retinoic acid.
Journal of neurochemistry.
51(6):1892-9
[PMID] 2903224.
1988
Effects of opioid peptides on human neuroblastoma cells.
NIDA research monograph.
87:111-7
[PMID] 2855093.
1988
Neuronal cell differentiation of human neuroblastoma cells by retinoic acid plus herbimycin A.
Cancer research.
48(22):6530-4
[PMID] 2846152.
1986
Affinities of glucocorticoids for glucocorticoid receptors in the human lung.
Agents and actions.
17(3-4):290-1
[PMID] 3962769.
1986
Delta opioid receptors in human neuroblastoma cell lines.
Brain research.
382(2):327-31
[PMID] 3019481.
1986
Development of a biotin-avidin probe for detecting opioid receptors.
NIDA research monograph.
75:33-6
[PMID] 2828982.
1986
HPLC determination of glucocorticoid alcohols, their phosphates and hydrocortisone in aqueous solutions and biological fluids.
Journal of pharmaceutical and biomedical analysis.
4(2):197-206
[PMID] 16867616.
1985
Simultaneous determination of glucocorticoid alcohols, their succinates and hydrocortisone in plasma.
Journal of pharmaceutical and biomedical analysis.
3(6):566-73
[PMID] 16867648.
1983
Identification of glucocorticoid receptors in normal and neoplastic adult human lung.
Research in experimental medicine. Zeitschrift fur die gesamte experimentelle Medizin einschliesslich experimenteller Chirurgie.
182(1):71-8
[PMID] 6856988.
Grants
Sep 2022
ACTIVE
Advancing In Vitro and (patho) Physiology-Based Pharmacokinetics Models to Understand and Predict Pulmonary Absorption and Tissue Retention of Inhaled Drugs
Role: Co-Investigator
Funding: US FOOD AND DRUG ADMN
Oct 2020
– Oct 2020
GSK Fellowship – Jose Francis Year 2
Role: Other
Funding: GLAXO SMITHKLINE
Oct 2019
– Jul 2020
GSK Fellowship – Jose Francis Year 1
Role: Principal Investigator
Funding: GLAXO SMITHKLINE
Sep 2019
– Dec 2022
Systematic evaluation of the ex-throat plume properties of MDI formulations
Role: Principal Investigator
Funding: US FOOD AND DRUG ADMN
Sep 2019
– Sep 2021
A Multiscale Computational Framework for Bioequivalence of Orally Inhaled Drugs
Role: Principal Investigator
Funding: CFD RESEARCH CORP
via US FOOD AND DRUG ADMN
Jul 2019
– Jul 2020
Clinical Pharmacokinetics/Dynamics Fellowship 2018-2019 – Sagar Bachav
Role: Principal Investigator
Funding: GLAXO SMITHKLINE
Jul 2018
– Jul 2019
Clinical Pharmacokinetics/Dynamics Fellowship 2017-2018 – Sagar Bachav
Role: Principal Investigator
Funding: GLAXO SMITHKLINE
Sep 2016
– Mar 2018
Pharmacokinetic Comparison of Locally Acting Orally Inhaled Drug Products
Role: Co-Investigator
Funding: US FOOD AND DRUG ADMN
Feb 2016
– Dec 2016
Methacholine stability test over 8 months (months 0-8)-batch 2
Role: Principal Investigator
Funding: COMPLEWARE CORPORATION
Aug 2015
– Nov 2016
Methacholine Stability Testing with Ion Exchange Method
Role: Principal Investigator
Funding: COMPLEWARE CORPORATION
Jul 2015
– Jan 2017
Further Characterization of the Modified Chi-square Ratio Test for the Comparison of Cascade Impactor Profiles
Role: Principal Investigator
Funding: INTL PHARM AEROSOL CONSRT REG AND SCIENC
Apr 2015
– Mar 2021
Peptidic Kappa Opioid Receptor Ligands as Potential Treatments for Drug Addiction
Role: Project Manager
Funding: NATL INST OF HLTH NIDA
Mar 2015
– Dec 2018
Determination of Drug Levels in Interstitial Fluid for Therapeutic IgG by Microdialysis and its Relevance for Pharmacokinetic and Pharmacodynamic
Role: Principal Investigator
Funding: HOFFMANN LA ROCHE
Dec 2014
– Feb 2020
Comprehensive Evaluation of Formulation Effects on Metered Dose Inhaler Performance
Role: Principal Investigator
Funding: US FOOD AND DRUG ADMN
Sep 2013
– Apr 2020
Study to Investigate the Sensitivity of Pharmacokinetics in Detecting Differences in Physicochemical Properties of the Active in Suspension Nasal Products for Local Action
Role: Co-Investigator
Funding: US FOOD AND DRUG ADMN
Sep 2013
– Dec 2016
Stability of Fluticasone Proprionate Capsules for Inhalation
Role: Principal Investigator
Funding: FEFA
via US DEPT OF HLTH AND HUMAN SER
Sep 2013
– Feb 2017
An Optimized Dissolution Test System for Orally Inhaled Drugs: Development and Va
Role: Principal Investigator
Funding: US FOOD AND DRUG ADMN
Aug 2012
– Jul 2017
Does P-glycoprotein Restrict Access of Budesonide but not Fluticasone Propionate to the Placenta and Fetus?
Role: Principal Investigator
Funding: ASTRAZENECA
Sep 2011
– Sep 2016
Pharmacokinetic Comparison of Locally Acting Inhaled Drug Products pt II
Role: Principal Investigator
Funding: FEFA
via US DEPT OF HLTH AND HUMAN SER
Education
Ph.D.
1984
·
University of Munster
B.Sc.
1980
·
Elisabeth Apotheke
Contact Details
Phones:
- Business:
- (352) 273-7861
Emails:
- Business:
- hochhaus@ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100494
GAINESVILLE FL 32610 - Business Street:
-
MSB P3-33
MSB P3-33
GAINESVILLE FL 326110001